Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial.
Rejnmark L, Gosmanova EO, Khan AA, Makita N, Imanishi Y, Takeuchi Y, Sprague S, Shoback DM, Kohlmeier L, Rubin MR, Palermo A, Schwarz P, Gagnon C, Tsourdi E, Zhao C, Makara MA, Ominsky MS, Lai B, Ukena J, Sibley CT, Shu AD. Rejnmark L, et al. Among authors: makara ma. Adv Ther. 2024 Apr 30. doi: 10.1007/s12325-024-02843-8. Online ahead of print. Adv Ther. 2024. PMID: 38691316
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions.
Marshall AD, Willing AR, Kairouz A, Cunningham EB, Wheeler A, O'Brien N, Perera V, Ward JW, Hiebert L, Degenhardt L, Hajarizadeh B, Colledge S, Hickman M, Jawad D, Lazarus JV, Matthews GV, Scheibe A, Vickerman P, Dore GJ, Grebely J; Global HCV and HIV Treatment Restrictions Group. Marshall AD, et al. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):366-382. doi: 10.1016/S2468-1253(23)00335-7. Epub 2024 Feb 15. Lancet Gastroenterol Hepatol. 2024. PMID: 38367631 Review.
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V; MAESTRO-NASH Investigators. Harrison SA, et al. N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000. N Engl J Med. 2024. PMID: 38324483 Clinical Trial.
[Screening and treatment of hepatitis C virus in prisons: 10 years of experience].
Werling K, Makara M, Nemesi K, Horváth G, Schneider F, Bali I, Enyedi J, Jancsik V, Káfony A, Lesch M, Lombay B, Müller Z, Ozsvár Z, Patai Á, Péterfi Z, Pusztay M, Szabó O, Szlávik J, Tóth T, Varga M, Gács J, Újhelyi E, Nemes Nagy A. Werling K, et al. Among authors: makara m. Orv Hetil. 2022 May 29;163(22):871-878. doi: 10.1556/650.2022.32492. Print 2022 May 29. Orv Hetil. 2022. PMID: 35895613 Hungarian.
HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons.
Flisiak R, Zarębska-Michaluk D, Ciupkeviciene E, Drazilova S, Frankova S, Grgurevic I, Hunyady B, Jarcuska P, Kupčinskas L, Makara M, Saulite-Vanaga G, Simonova M, Sperl J, Tolmane I, Vince A. Flisiak R, et al. Among authors: makara m. Viruses. 2022 Feb 26;14(3):482. doi: 10.3390/v14030482. Viruses. 2022. PMID: 35336889 Free PMC article. Review.
151 results